DISCOVER
$0.59
NASDAQ:
RENB
+0.08 ( 14.71% )
Pricing delayed by 20 minutes
Last updated: 14/10/2024 15:48 EST
Imagine this: a world where cancer is caught early enough to be effectively treated without the need for debilitating surgery or destructive chemotherapy. A world where we do not have to suffer the loss of loved ones who leave us too early. Thanks to Al’s power and genetic sequencing advances, Renovaro is taking the lead in making this vision a reality by combining advanced diagnostic and personalized immunotherapy.
Explainable AI Engine
- AI system agnostic, trusted and versatile
- Capable of handling data from multiple sources
Diagnostics
- Early diagnosis, recurrence and response to treatment
- Can be applied to liquid biopsies
Therapeutics
- A universal off the shelf approach for various indications
- Allowing non-toxic universal treatment
News
September 19, 2024
PersonalAIze and Cube Forge Groundbreaking Partnership
Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes.
September 17, 2024
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform
Assessment by specialist Ai team from “PersonalAIze” Highlights the Strenght, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform.
September 13, 2024
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RenovaroCube is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
September 11, 2024
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of Cube, currently a wholly owned subsidiary. This opportunity will be available to all potential investors including current shareholders of RENB.
What we do
Renovaro Cube is working to transform cancer detection through its advanced AI/Machine Learning platform that harnesses the power of multi-omics analysis and differential molecular capabilities. With access to vast amounts of big data, Renovaro Cube is at the forefront of leveraging data mining techniques, resulting in the development of over 2600 proprietary biomarker panels – and counting.
We are rapidly working to expand our platform for as many cancers as we possibly can, as well as other diseases. Utilizing differential molecular diagnosis and multi-omic analysis, our platform aims to enhance accuracy in the detection of multiple cancers, with a view to identifying them even before traditional methods may find them. Our state-of-the-art AI/ML platform supports precision oncology, offering significant capabilities in minimal residual disease and recurrence monitoring. Thus, supporting patients in readmission allows routine checks, via blood draw, to be carried out, assessed, and then acted upon.
Additionally, our unique library of over 2600 biomarker panels offers the flexibility to create custom panels for the pharmaceutical industry. The first steps will be to assist in clinical studies through effective patient stratification and accelerating drug discovery timelines by providing quicker results through in-silico approaches.
The Challenge
Fifty percent of us will develop cancer and half will die of this disease. Early diagnosis will dramatically increase survival but the diagnosis often comes too late may be discovered too offer an effective a cure. When cancer is diagnosed treatment, fails in more than 70% of the cases. Selecting the right treatment for the right patient is essential to reduce side effects and increase survival.
Treatment of advanced cancer is more expensive, complex, and more disruptive for the patient.
Wouldn’t it be great if we could detect cancer at the earliest stage possible and select the right treatment immediately…
The Solution
Modern medicine requires a vertical integration by combining diagnostics and therapeutics to select the right treatment for the right patient allowing a first time right. At Renevaro we are coomited to offer an all in one solution for patients with cancer.
Patient Benefit
Faster diagnosis of cancer and other diseases would mean that the diagnosis could be made sooner after the onset of disease, making treatment simpler, quicker and less disruptive for the patient.
In established disease that has been treated and even considered cured, patients would benefit from follow-up surveillance that is sensitive and accurate.
Supporting our doctors
We offer an integrated solution for doctor by offering a large array of diagnostic products from early diagnosis, treatment selection, response to treatment and follow-up and therapeutics that are personalized. All these products are offered in one understandable and actionable solution for individual patients supporting the full patient journey. This apporach will increase survival and treatment response and reduce the burden on the healthcare system the individual doctor.
Team
RenovaroCube brings together powerful technology and a multi-disciplinary team of molecular biologists, biomedical scientists, medical doctors, software engineers, data scientists and data miners, who are passionate about actively contributing to the success of each project.
Together, we are empowering biomedicine with big data science and realizing the promise of AI in oncology.